DK173423B1 - Rifapentin-hydrohalogenider, fremgangsmåde til fremstilling deraf, farmaceutisk dosisform indeholdende dem samt deres anven - Google Patents

Rifapentin-hydrohalogenider, fremgangsmåde til fremstilling deraf, farmaceutisk dosisform indeholdende dem samt deres anven Download PDF

Info

Publication number: DK173423B1
Authority: DK; Denmark
Prior art keywords: rifapentin; solid; acid addition; addition salt; bromine
Prior art date: 1988-07-13

Application number

DK199002925A

Other languages

Danish (da)

English (en)

Other versions

DK292590A (da

DK292590D0 (da

Inventor

Emilio Occelli

Bruno Cavalleri

Marino Nebuloni

Original Assignee

Lepetit Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-07-13

Filing date

1990-12-10

Publication date

2000-10-09

1990-12-10 Application filed by Lepetit Spa filed Critical Lepetit Spa

1990-12-10 Publication of DK292590A publication Critical patent/DK292590A/da

1990-12-10 Publication of DK292590D0 publication Critical patent/DK292590D0/da

2000-10-09 Application granted granted Critical

2000-10-09 Publication of DK173423B1 publication Critical patent/DK173423B1/da

Links

WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 title claims abstract description 54
238000000034 method Methods 0.000 title claims description 16
239000002552 dosage form Substances 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title claims description 11
239000007787 solid Substances 0.000 claims abstract description 34
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 20
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 19
239000002253 acid Substances 0.000 claims description 17
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
238000002425 crystallisation Methods 0.000 claims description 15
230000008025 crystallization Effects 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 13
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
229910052794 bromium Inorganic materials 0.000 claims description 8
239000000460 chlorine Substances 0.000 claims description 8
229910052801 chlorine Inorganic materials 0.000 claims description 8
125000001309 chloro group Chemical group Cl* 0.000 claims description 8
238000000354 decomposition reaction Methods 0.000 claims description 8
238000002844 melting Methods 0.000 claims description 8
230000008018 melting Effects 0.000 claims description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
125000001246 bromo group Chemical group Br* 0.000 claims 3
239000011260 aqueous acid Substances 0.000 claims 1
239000011541 reaction mixture Substances 0.000 claims 1
230000000844 anti-bacterial effect Effects 0.000 abstract description 2
229960002599 rifapentine Drugs 0.000 abstract description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
150000001875 compounds Chemical class 0.000 description 12
239000000243 solution Substances 0.000 description 9
238000002329 infrared spectrum Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000002585 base Substances 0.000 description 6
238000001035 drying Methods 0.000 description 5
239000012458 free base Substances 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000002076 thermal analysis method Methods 0.000 description 5
230000007704 transition Effects 0.000 description 5
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
230000004580 weight loss Effects 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000008298 dragée Substances 0.000 description 3
238000000227 grinding Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000007940 sugar coated tablet Substances 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001938 differential scanning calorimetry curve Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000155 melt Substances 0.000 description 2
239000011707 mineral Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
239000008213 purified water Substances 0.000 description 2
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
229960001225 rifampicin Drugs 0.000 description 2
-1 rifapentin halides Chemical class 0.000 description 2
239000011343 solid material Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
BBNQHOMJRFAQBN-UPZFVJMDSA-N 3-formylrifamycin sv Chemical compound OC1=C(C(O)=C2C)C3=C(O)C(C=O)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BBNQHOMJRFAQBN-UPZFVJMDSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229910016523 CuKa Inorganic materials 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
241000700159 Rattus Species 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940086763 ascorbic acid 100 mg Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002485 combustion reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000004174 erythrosine Substances 0.000 description 1
MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000010304 firing Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
239000012433 hydrogen halide Substances 0.000 description 1
229910000039 hydrogen halide Inorganic materials 0.000 description 1
238000005213 imbibition Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
IYPZRUYMFDWKSS-UHFFFAOYSA-N piperazin-1-amine Chemical class NN1CCNCC1 IYPZRUYMFDWKSS-UHFFFAOYSA-N 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000012958 reprocessing Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
239000002966 varnish Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Dental Preparations (AREA)
Fats And Perfumes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Liquid Crystal Substances (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

DK199002925A 1988-07-13 1990-12-10 Rifapentin-hydrohalogenider, fremgangsmåde til fremstilling deraf, farmaceutisk dosisform indeholdende dem samt deres anven DK173423B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8816620		1988-07-13
GB888816620A GB8816620D0 (en)	1988-07-13	1988-07-13	Rifapentine hydrohalides
PCT/EP1989/000694 WO1990000553A1 (en)	1988-07-13	1989-06-21	Rifapentine hydrohalides
EP8900694		1989-06-21

Publications (3)

Publication Number	Publication Date
DK292590A DK292590A (da)	1990-12-10
DK292590D0 DK292590D0 (da)	1990-12-10
DK173423B1 true DK173423B1 (da)	2000-10-09

Family

ID=10640347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK199002925A DK173423B1 (da)	1988-07-13	1990-12-10	Rifapentin-hydrohalogenider, fremgangsmåde til fremstilling deraf, farmaceutisk dosisform indeholdende dem samt deres anven

Country Status (19)

Country	Link
US (1)	US5306715A (de)
EP (1)	EP0440642B1 (de)
JP (1)	JP2716553B2 (de)
KR (1)	KR0135312B1 (de)
CN (1)	CN1039421A (de)
AT (1)	ATE111101T1 (de)
AU (1)	AU632754B2 (de)
CA (1)	CA1339215C (de)
DE (1)	DE68918107T2 (de)
DK (1)	DK173423B1 (de)
ES (1)	ES2018374A6 (de)
GB (1)	GB8816620D0 (de)
GR (1)	GR1002222B (de)
HU (1)	HU210716A9 (de)
IE (1)	IE65812B1 (de)
IL (1)	IL90892A0 (de)
PT (1)	PT91132B (de)
WO (1)	WO1990000553A1 (de)
ZA (1)	ZA894991B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
KR0170000B1 (ko) *	1990-06-29	1999-02-01	레나토 스가르비	순수한 결정 형태의 리파펜틴
HRP20000162B1 (en)	2000-03-20	2004-06-30	Pliva D D	Amorphous torasemide modification
JP4393098B2 (ja) *	2002-06-21	2010-01-06	独立行政法人科学技術振興機構	アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
CN101219992B (zh) *	2003-02-12	2011-08-31	日产化学工业株式会社	匹伐他汀钙的晶形
ITMI20032144A1 (it) *	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
SI1698630T1 (sl) *	2005-03-03	2015-01-30	Alfa Wassermann S.P.A.	Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
JP2007246514A (ja) *	2006-02-14	2007-09-27	Toyama Chem Co Ltd	ピペラシリンナトリウムの新規な結晶
MX2009008124A (es) *	2007-01-31	2009-10-08	Toyama Chemical Co Ltd	Cristal nuevo de piperacilina sodica.
IT1398550B1 (it)	2010-03-05	2013-03-01	Alfa Wassermann Spa	Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2013212008A1 (en)	2012-01-25	2014-07-10	Alfa Wassermann S.P.A.	Rifaximin derivative and uses thereof
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US20240199642A1 (en) *	2021-04-21	2024-06-20	Interquim S.A. De C.V.	Method for obtaining rifapentine with a new crystalline form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR208F (de) *	1964-07-31
GB1478563A (en) *	1975-03-05	1977-07-06	Lepetit Spa	Rifamycin derivatives
FR2309556A1 (fr) *	1975-04-29	1976-11-26	Aries Robert	Aminoguanidines derivees de la rifamycine
US4876258A (en) *	1987-08-13	1989-10-24	Ciba-Geigy Corporation	Biphenylyl compounds
JPH02501301A (ja) *	1987-09-25	1990-05-10	チバ‐ガイギー　アクチェンゲゼルシャフト	４‐（トリアルキルベンジル）‐ピペラジニル化合物のジアシル誘導体

1988
- 1988-07-13 GB GB888816620A patent/GB8816620D0/en active Pending
1989
- 1989-06-21 AT AT89907141T patent/ATE111101T1/de not_active IP Right Cessation
- 1989-06-21 DE DE68918107T patent/DE68918107T2/de not_active Expired - Lifetime
- 1989-06-21 EP EP89907141A patent/EP0440642B1/de not_active Expired - Lifetime
- 1989-06-21 US US07/635,172 patent/US5306715A/en not_active Expired - Lifetime
- 1989-06-21 KR KR1019900700524A patent/KR0135312B1/ko not_active Expired - Lifetime
- 1989-06-21 JP JP1506684A patent/JP2716553B2/ja not_active Expired - Lifetime
- 1989-06-21 WO PCT/EP1989/000694 patent/WO1990000553A1/en not_active Ceased
- 1989-06-21 AU AU37702/89A patent/AU632754B2/en not_active Expired
- 1989-06-30 ZA ZA894991A patent/ZA894991B/xx unknown
- 1989-07-06 IL IL90892A patent/IL90892A0/xx unknown
- 1989-07-10 CA CA000605232A patent/CA1339215C/en not_active Expired - Fee Related
- 1989-07-11 PT PT91132A patent/PT91132B/pt not_active IP Right Cessation
- 1989-07-12 ES ES8902463A patent/ES2018374A6/es not_active Expired - Lifetime
- 1989-07-12 IE IE224789A patent/IE65812B1/en not_active IP Right Cessation
- 1989-07-13 CN CN89104777A patent/CN1039421A/zh active Pending
- 1989-07-13 GR GR890100448A patent/GR1002222B/el not_active IP Right Cessation
1990
- 1990-12-10 DK DK199002925A patent/DK173423B1/da not_active IP Right Cessation
1995
- 1995-01-04 HU HU95P/P00062P patent/HU210716A9/hu unknown

Also Published As

Publication number	Publication date
IE892247L (en)	1990-01-13
AU3770289A (en)	1990-02-05
WO1990000553A1 (en)	1990-01-25
GB8816620D0 (en)	1988-08-17
DK292590A (da)	1990-12-10
GR890100448A (el)	1990-06-27
HU210716A9 (en)	1995-06-28
PT91132A (pt)	1990-02-08
EP0440642B1 (de)	1994-09-07
KR900701798A (ko)	1990-12-04
HK1005455A1 (en)	1999-01-08
US5306715A (en)	1994-04-26
ATE111101T1 (de)	1994-09-15
CN1039421A (zh)	1990-02-07
DE68918107D1 (de)	1994-10-13
DK292590D0 (da)	1990-12-10
PT91132B (pt)	1994-12-30
ZA894991B (en)	1990-08-29
IE65812B1 (en)	1995-11-15
JP2716553B2 (ja)	1998-02-18
JPH03506025A (ja)	1991-12-26
EP0440642A1 (de)	1991-08-14
IL90892A0 (en)	1990-02-09
AU632754B2 (en)	1993-01-14
DE68918107T2 (de)	1995-01-26
GR1002222B (en)	1996-04-17
ES2018374A6 (es)	1991-04-01
CA1339215C (en)	1997-08-05
KR0135312B1 (ko)	1998-04-23

Legal Events

Date	Code	Title	Description
2000-10-09	B1	Patent granted (law 1993)
2009-07-06	PUP	Patent expired

Publication	Publication Date	Title
NZ248285A (en)	1994-07-26	Hydrochloride salt of a triazolylthiomethylthio cephem derivative and medicaments
NO312513B1 (no)	2002-05-21	Mesylat-trihydrat av 5-(2-(4-(1,2-benzoisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on(=ziperasidone), og farmasöytisk blanding for behandling avpsykotisk forstyrrelse
KR20020079998A (ko)	2002-10-21	5-[4-[2-(ｎ-메틸-ｎ-(2-피리딜)아미노)에톡시]벤질]티아졸리딘-2,4-디온의 하이드로클로라이드 염
NO312514B1 (no)	2002-05-21	Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1- piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), og farmasöytisk blanding for behandling av enpsykotisk forstyrrelse
US20030144517A1 (en)	2003-07-31	Chiral fluoroquinolone arginine salt forms
PL152022B1 (en)	1990-10-31	Method of manufacture of new crystalline monohydrate 1-carbacephalosporin
WO2018109786A1 (en)	2018-06-21	Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
CA1339215C (en)	1997-08-05	Rifapentine hydrohalides
JPH02178281A (ja)	1990-07-11	β―ラクタム抗生物質の水和物
WO2018167652A1 (en)	2018-09-20	Process for preparation of amorphous form of venetoclax
JPS60215689A (ja)	1985-10-29	結晶性セフタジダイム塩
AU2018349284B2 (en)	2023-11-16	New salt and solid state forms of escitalopram
CA2403264A1 (en)	2001-11-15	Chiral fluoroquinolizinone arginine salt forms
NO320609B1 (no)	2005-12-27	Hydroklorid-hydrat, anvendelse og fremstilling derav, samt farmasoytisk preparat.
KR20010112446A (ko)	2001-12-20	티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
KR100364941B1 (ko)	2003-02-19	1-[5-메탄설폰아미도인돌릴-2-카보닐]-4-[3-(1-메틸에틸아미노)-2-피리디닐]피페라진의신규한결정형태
HUE026460T2 (en)	2016-05-30	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts
CA2034592C (en)	2001-06-05	Crystalline hydrochloride of new beta-lactam antibiotic and process therefor
SK146293A3 (en)	1994-12-07	Cefalosporine salts and method of their production
HK1005455B (en)	1999-01-08	Rifapentine hydrohalides
CN112409285A (zh)	2021-02-26	噁唑烷酮类化合物的晶型及其制备方法和应用
US20240199642A1 (en)	2024-06-20	Method for obtaining rifapentine with a new crystalline form
MXPA98009242A (en)	1999-09-01	Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-